The global pharmaceutical sector has around $700 billion at its disposal to acquire other companies and invest in research and development, according to Goldman Sachs Research. That war chest will be important as patents expire for some of the industry’s blockbuster drugs. “The pharmaceutical industry will need growth, and is sitting on a tremendous amount of cash,” says Asad Haider, head of the healthcare business unit in Goldman Sachs Research. “The baseline expectation is that there is going to be continued M&A.” In addition, he says there’s been tremendous progress in innovation and there are signs that surgical procedure volumes are on the rise.
Read the full article: Pharmaceutical Companies Have $700B for Acquisitions and Investment //
Source: https://www.goldmansachs.com/intelligence/pages/pharmaceutical-companies-have-700-billion-for-acquisition.html